-
公开(公告)号：US20230390272A1
公开(公告)日：2023-12-07
申请号：US18249548
申请日：2021-10-20
Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
Inventor： Michael HAYDEN , Michal GEVA
IPC: A61K31/451 , A61K31/444 , A61P25/22 , A61P25/24 , A61P25/28
CPC classification number: A61K31/451 , A61K31/444 , A61P25/22 , A61P25/24 , A61P25/28
Abstract: The invention provides a method of reducing anxiety and/or depression in a subject comprising administering to the subject a pharmaceutical composition comprising pridopidine or pharmaceutical acceptable salts and at least one of compounds 1-8 or pharmaceutical acceptable salt thereof described herein, effective to reduce anxiety and/or depression in a subject.
-
公开(公告)号：US20210106572A1
公开(公告)日：2021-04-15
申请号：US16952123
申请日：2020-11-19
Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
Inventor： Michal GEVA , Ralph LAUFER , Michael HAYDEN
IPC: A61K31/451 , A61P25/14 , A61K9/00
Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.
-
公开(公告)号：US20210030734A1
公开(公告)日：2021-02-04
申请号：US17076069
申请日：2020-10-21
Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
Inventor： Michal GEVA , Michael Hayden
IPC: A61K31/451 , A61P25/28 , A61K9/00
Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine.
-
公开(公告)号：US20250082619A1
公开(公告)日：2025-03-13
申请号：US18950102
申请日：2024-11-17
Applicant: Prilenia Neurotherapeutics Ltd.
Inventor： Michael HAYDEN , Michal GEVA
Abstract: Provided herein a method of maintaining, improving, or lessening the decline of functional capacity, cognition, motor function, disease progression and quality of life of a subject afflicted with Huntington disease, including those afflicted with early-stage Huntington disease (HD1 and HD2, TFC 7-13) by orally administering to the subject a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240261273A1
公开(公告)日：2024-08-08
申请号：US18630030
申请日：2024-04-09
Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
Inventor： Michael HAYDEN , Michal GEVA
IPC: A61K31/451 , A61P25/28 , A61P27/06
CPC classification number: A61K31/451 , A61P25/28 , A61P27/06
Abstract: This application provides a composition comprising pridopidine or pharmaceutically acceptable salt thereof and at least one of compounds 1-8 (described herein) or pharmaceutically acceptable salt thereof for use in the treatment of neurodegenerative eye disease, symptoms thereof, and additional neurodegenerative disorders.
-
Patent Agency Ranking
公开(公告)号：US20230414596A1
公开(公告)日：2023-12-28
申请号：US18253221
申请日：2021-11-19
Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
Inventor： Michael HAYDEN , Michal GEVA
IPC: A61K31/451 , A61K31/4418 , A61K31/4545 , A61P25/00
CPC classification number: A61K31/451 , A61K31/4418 , A61K31/4545 , A61P25/00
Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject a pharmaceutical composition comprising pridopidine or pharmaceutical acceptable salts and at least one of compounds or pharmaceutical acceptable salt thereof disclosed herein, so as to thereby treat the subject.
-
公开(公告)号：US20230355595A1
公开(公告)日：2023-11-09
申请号：US18324980
申请日：2023-05-28
Applicant: Prilenia Neurotherapeutics Ltd.
Inventor： Michael HAYDEN , Michal GEVA
Abstract: Provided herein a method of maintaining, improving, or lessening the decline of functional capacity, cognition, motor function and quality of life of a subject afflicted with Huntington disease, including those afflicted with early-stage Huntington disease (HD1 and HD2, TFC 7-13) by orally administering to the subject a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20230330073A1
公开(公告)日：2023-10-19
申请号：US18306257
申请日：2023-04-25
Applicant: Prilenia Neurotherapeutics Ltd.
Inventor： Michael HAYDEN , Michal GEVA
Abstract: This invention provides a method of maintaining, improving or lessening the decline of functional capacity or motor function in a human patient in a human patient with Huntington disease (HD) comprising orally administering to the patient a pharmaceutical composition comprising pridopidine.
-
公开(公告)号：US20230181548A1
公开(公告)日：2023-06-15
申请号：US18164587
申请日：2023-02-05
Applicant: Prilenia Neurotherapeutics Ltd.
Inventor： Michael HAYDEN , Michal GEVA
Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.
-
公开(公告)号：US20210220342A1
公开(公告)日：2021-07-22
申请号：US17182605
申请日：2021-02-23
Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
Inventor： Michael HAYDEN , Michal GEVA , Ana Cristina CARVALHO REGO
Abstract: The subject invention provides a method for treating a subject afflicted with a disease, disorder, or condition associated with mitochondrial dysfunction or ER stress, comprising administering to the subject a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.019 seconds)
